Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing
The Motley Fool
by newsfeedback@fool.com (Jake Lerch)March 4, 2026
This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline.
Verticals
financeinvesting
Originally published on The Motley Fool on 3/4/2026